November 6, 2025

Munich-based Tubulis secures €308 million to advance antibody-drug conjugate innovation

Tubulis

Investment raised

EUR 308m

Valuation

Stage

Sector

Region

Investors

Led by Venrock Healthcare Capital Partners, with participation from Wellington Management and Ascenta Capital, alongside existing investors including Nextech Invest, EQT Life Sciences, Frazier Life Sciences, Andera Partners, Deep Track Capital, Bayern Kapital, Fund+, OCCIDENT, Seventure Partners, and HTGF.